Dr. Rosenblatt is Chief Medical Officer of Flagship Pioneering. Till recently he was Executive Vice President and Chief Medical Officer at Merck & Co. Previously he served as Dean of Tufts University School of Medicine. Prior to that, he held the appointment of George R. Minot Professor of Medicine at Harvard Medical School and Chief of the Division of Bone and Mineral Metabolism Research at Beth Israel Deaconess Medical Center (BIDMC). He served as the President of BIDMC from 1999-2001. Previously, he was the Harvard Faculty Dean and Senior Vice President for Academic Programs at CareGroup and BIDMC and a founder of the Carl J. Shapiro Institute for Education and Research at Harvard Medical School and BIDMC, a joint venture whose mission is to manage the academic enterprise and promote academic innovation.
Prior to that, Dr. Rosenblatt served as Director of the Harvard-MIT Division of Health Sciences and Technology, during which time he led a medical education organization for MD, PhD, and MD-PhD training jointly sponsored by Harvard and MIT. And earlier, he was Senior Vice President for Research at Merck Sharp & Dohme Research Laboratories where he co-led the worldwide development team for alendronate (FOSAMAX), Merck's bisphosphonate for osteoporosis and bone disorders. In addition, he directed drug discovery efforts in molecular biology, bone biology, virology, cancer research, lipid metabolism, and cardiovascular research in the United States, Japan, and Italy. He also headed Merck Research's worldwide University and Industry Relations Department.
He is the recipient of the Fuller Albright Award for his work on parathyroid hormone and the Vincent du Vigneaud Award in peptide chemistry and biology, and the Chairman’s Award from Merck. His research is in the field of hormonal regulation of calcium metabolism, osteoporosis, and cancer metastasis to bone. His major research projects are in the design of peptide hormone antagonists for parathyroid hormone and the tumor-secreted parathyroid hormone-like protein, isolation/characterization of receptors and mapping hormone—receptor interactions, elucidating the mechanisms by which breast cancer “homes” to bone, and osteoporosis and bone biology.
He has been an active participant in the biotechnology industry, serving on the board of directors and scientific advisory boards of several biotech companies. He was a scientific founder of ProScript, the company that discovered bortezomib (Velcade), now Takeda Millennium Pharmaceutical’s drug for multiple myeloma and other malignancies. He was a member of the Board of Scientific Counselors of the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH. He has been elected to the American Society of Clinical Investigation, the Association of American Physicians, to Fellowship in the American Association for the Advancement of Science and the American College of Physicians, and the presidency of the American Society of Bone and Mineral Research. He has testified before a Senate Hearing on U.S. biomedical research priorities in 1997 and in 2011 as a consultant to the U.S. President's Council of Advisors on Science and Technology.
From 1981 to 1984, he served as Chief of the Endocrine Unit, Massachusetts General Hospital. He received his undergraduate degree summa cum laude from Columbia and his MD magna cum laude from Harvard. His internship, residency, and endocrinology training were all at the Massachusetts General Hospital.